Table 2

The relationship between clinico-pathological characteristics and ER status of patients with primary operable invasive ductal breast cancer
Oestrogen receptor negative (n = 124) Oestrogen receptor positive (n = 237) ( P -value)
Age (≤50/>50 years) 43/81 52/185 0.009
Size (≤20/21-50/>50 mm) 57/62/4 149/83/5 0.004
Grade (I/II/III) 3/22/99 61/125/51 <0.001
Involved lymph node (0/1-3/>3) 65/30/28 130/68/35 0.211
Progesterone -receptor status (PR-/PR+) 117/5 72/161 <0.001
HER-2 status (HER-2 -/HER-2+) 80/41 212/24 <0.001
Ki-67 status (Low Ki-67/High Ki-67) 99/24 160/68 0.036
LVI (Absent/Present) 56/68 161/76 <0.001
MVD (CD34+) (tertiles 1, 2, 3) 38/41/44 83/84/61 0.106
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) 44/80 89/148 0.699
Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none) 26/19/66/11 158/61/8/8 <0.001
Cancer specific survival (months)* 130 (118–142) 156 (150–162) 0.001

*Mean (95% CI).

Mohammed et al.

Mohammed et al. BMC Clinical Pathology 2013 13:31   doi:10.1186/1472-6890-13-31

Open Data